Anavex Life Sciences Corp

(NASDAQ:AVXL)

Latest On Anavex Life Sciences Corp (AVXL):

Date/Time Type Description Signal Details
2023-05-09 09:59 ESTNewsAnavex Life Sciences GAAP EPS of -$0.17 beats by $0.01N/A
2023-05-09 09:59 ESTNewsAnavex Life Sciences Corp. (AVXL) Q2 2023 Earnings Call TranscriptN/A
2023-05-08 21:26 ESTNewsAnavex Life Sciences Q2 2023 Earnings PreviewN/A
2023-05-04 09:38 ESTNewsAnavex And The Antioxidant Treatment Of Alzheimer's DiseaseN/A
2023-04-06 10:52 ESTNewsBiogen And Eisai, Cassava Sciences, And Anavex: Clinical Trial Results In Need Of RevisionsN/A
2023-03-31 01:41 ESTNewsAnavex gains on long-term data for Parkinson’s disease therapyN/A
2023-03-16 14:51 ESTNewsBuy Anavex For Its Likely Positive Alzheimer's Disease DataN/A
2023-03-08 22:50 ESTNewsAnavex: Many Questions Answered, A Few Still Left, But Things Are Progressing WellN/A
2023-02-09 22:02 ESTNewsAnavex Life Sciences: Recent Earnings Reveals Strong Cash Position To Get ANAVEX 2-73 Through FDAN/A
2023-02-07 16:44 ESTNewsAnavex Life Sciences GAAP EPS of -$0.17 beats by $0.02N/A
2023-02-07 16:44 ESTNewsAnavex Life Sciences Corp. (AVXL) Q1 2023 Earnings Call TranscriptN/A
2023-02-07 16:43 ESTNewsAnavex hits two-month high after Q1 FY23 resultsN/A
2023-02-06 15:12 ESTNewsAnavex Life Sciences Q1 2023 Earnings PreviewN/A
2023-02-02 15:43 ESTNewsAnavex gains as trial for Rett syndrome candidate exceeds enrollment targetN/A
2023-01-31 00:23 ESTNewsApproval For Anavex's Blarcamesine Looks Inevitable After Biogen's Leqembi ApprovedN/A
2023-01-17 17:52 ESTNewsAnavex: Drug Treatments For Early Alzheimer's DiseaseN/A
2023-01-12 19:56 ESTNewsAnavex: Despite Positive Spin, No Clarity On AnomaliesN/A
2023-01-06 22:58 ESTNewsLilly, Anavex, other Alzheimer's drug developers rise modestly on Biogen lecanemab approvalN/A
2022-12-21 18:35 ESTNewsHow Well Does Anavex's New Alzheimer's Drug Compare Against Biogen's New Drug?N/A
2022-12-10 07:25 ESTNewsAnavex: A Thorough Approach To The DataN/A
2022-12-08 04:30 ESTNewsAnavex Life Sciences stock slides as downgraded to neutral at Cantor FitzgeraldN/A
2022-12-06 15:57 ESTNewsAnavex Life Sciences: The Little Company That DidN/A
2022-12-04 07:23 ESTNewsAnavex's Alzheimer's Results Leave Much To Be DesiredN/A
2022-12-02 19:33 ESTNewsAnavex surges 40% as drug improves cognitive function in Alzheimer's patients, meets trial's goalsN/A
2022-12-02 19:32 ESTNewsJones sees Anavex as 'clear M&A target' after Alzheimer's drug's trial successN/A
2022-11-30 14:05 ESTNewsAnavex Life Sciences: Market Unimpressed As Major Alzheimer's Data Readout ArrivesN/A
2022-11-29 21:24 ESTNewsAnavex defended at Cantor on prospects for rare disease therapyN/A
2022-11-29 02:23 ESTNewsAnavex Life Sciences Corp. (AVXL) Q4 2022 Earnings Call TranscriptN/A
2022-11-29 02:23 ESTNewsAnavex drops 16% after fiscal 2022 updateN/A
2022-11-28 08:22 ESTNewsAnavex Life Sciences GAAP EPS of -$0.18 misses by $0.01N/A
2022-11-08 08:37 ESTNewsAnavex Life Sciences At A Pivotal MomentN/A
2022-11-07 15:31 ESTNewsAnavex therapy for Fragile X syndrome gets FDA orphan drug statusN/A
2022-09-29 23:01 ESTNewsBiogen, Eisai cool off after massive run-up following lecanemab Alzheimer's dataN/A
2022-09-21 22:13 ESTNewsAnavex wins new U.S. patent for lead candidateN/A
2022-09-19 19:30 ESTNewsAnavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease DementiaN/A
2022-09-08 07:56 ESTNewsAnavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's DiseaseN/A
2022-08-11 23:27 ESTNewsAnavex And The Debunking Of The Amyloid HypothesisN/A
2022-08-10 12:59 ESTNewsAnavex Life Sciences Corp. (AVXL) CEO Dr. Christopher Missling on Q3 2022 Results - Earnings Call TranscriptN/A
2022-08-09 19:18 ESTNewsAnavex Life Sciences GAAP EPS of -$0.16 beats by $0.01N/A
2022-08-08 20:39 ESTNewsAnavex Life Sciences Q3 2022 Earnings PreviewN/A
2022-08-01 22:33 ESTNewsAnavex gains on the effect of Alzheimer’s drug on genesN/A
2022-06-24 04:00 ESTNewsAnavex gains as Berenberg launches coverage with Buy ratingN/A
2022-06-02 22:17 ESTNewsAnavex's Blarcamesine: Why It May Treat Alzheimer's DiseaseN/A
2022-05-31 18:54 ESTNewsAnavex: Increasing Shareholder Value Against All OddsN/A
2022-05-11 00:41 ESTNewsAnavex Life Sciences GAAP EPS of -$0.14 beats by $0.03N/A
2022-05-11 00:40 ESTNewsAnavex Life Sciences GAAP EPS of -$0.14 beats by $0.05N/A
2022-05-11 00:40 ESTNewsAnavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q2 2022 Results - Earnings Call TranscriptN/A
2022-05-10 02:36 ESTNewsAnavex Life Sciences Q2 2022 Earnings PreviewN/A
2022-03-24 04:50 ESTNewsAnavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's DiseaseN/A
2022-03-15 17:38 ESTNewsAnavex posts mid-stage biomarker data for lead candidateN/A

About Anavex Life Sciences Corp (AVXL):

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.

AVXL Quotes by TradingView

See Advanced Chart

General

  • Name Anavex Life Sciences Corp
  • Symbol AVXL
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 20
  • Last Split Factor1:4
  • Last Split Date2015-10-07
  • Fiscal Year EndSeptember
  • IPO Date2006-08-02
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.anavex.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 23.64
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.50
  • Next Year EPS Estimate -$0.55
  • Next Quarter EPS Estimate -$0.11
  • Return on Assets -41%
  • Return on Equity -76%
  • Earnings Per Share -$0.60
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 1.03 billion
  • Analyst Target Price $15.2
  • Book Value Per Share $0.69
View More

Share Statistics

  • Shares Outstanding 69.49 million
  • Shares Float 67.14 million
  • % Held by Insiders 363%
  • % Held by Institutions 19.19%
  • Shares Short 3.96 million
  • Shares Short Prior Month 4.01 million
  • Short Ratio 0.47
  • Short % of Float 6%
  • Short % of Shares Outstanding 6%
View More

Technicals

  • Beta 0.63
  • 52 Week High $16.39
  • 52 Week Low $2.23
  • 50 Day Moving Average 12.26
  • 200 Day Moving Average 6.92
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Anavex Life Sciences Corp (AVXL) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Anavex Life Sciences Corp (AVXL) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-11$N/A-$0.12-$0.120%
2020-09-302020-12-28$N/A-$0.10-$0.1323.08%
2020-06-302020-08-06$N/A-$0.11-$0.1418.52%
2020-03-312020-05-07$N/A-$0.12-$0.1623.42%
2019-12-312020-02-06$N/A-$0.12-$0.120%
2019-09-302019-12-16$N/A-$0.07-$0.1552.4%
2019-06-302019-08-07$N/A-$0.14-$0.1715.71%
2019-03-312019-05-08$N/A-$0.17-$0.14-21.43%
2018-12-312019-02-07$N/A-$0.16-$0.13-23.08%
2018-09-302018-12-12$N/A-$0.13-$0.11-18.18%
2018-06-302018-08-09$N/A-$0.06-$0.1041.92%
2018-03-312018-05-10$N/A-$0.11-$0.10-10%
2017-12-312018-02-07$N/A-$0.09
2017-09-302017-12-11$N/A-$0.12-$0.10-20%
2017-06-302017-08-07$N/A-$0.09-$0.091.33%
2017-03-312017-05-10$N/A-$0.04-$0.0955.56%
2016-12-312017-02-07$N/A-$0.08-$0.1127.27%
2016-09-302016-12-12$N/A-$0.18
2016-06-302016-08-11$N/A-$0.06-$0.0924.59%
2016-03-312016-05-11$N/A-$0.06-$0.1660.81%
2015-12-312016-02-08$N/A-$0.12-$0.1414.29%
2015-09-302015-12-29$N/A-$0.21-$0.06-250%
2015-06-302015-08-17$N/A-$0.22
2015-03-312015-05-15$N/A-$0.12
2014-12-312015-02-18$N/A-$0.06
2014-09-302014-12-29$N/A-$0.20-$0.200%
2014-06-302014-08-13$N/A-$0.10
2014-03-312014-05-28$N/A-$0.11
2013-12-312014-02-26$N/A$0.03
2013-09-302013-09-30$N/A-$0.40
2013-06-302013-06-30$N/A-$0.02
2013-03-312013-03-31$N/A-$0.01
2012-12-312012-12-31$N/A-$0.06
2012-09-302012-09-30$N/A-$0.10
2012-06-302012-06-30$N/A-$0.64
2012-03-312012-03-31$N/A-$0.13
2011-12-312011-12-31$N/A-$0.33
2011-09-302011-09-30-$0.23
2011-06-302011-06-30$N/A-$0.25
2011-03-312011-03-31-$0.31
2010-12-312010-12-31-$0.31
2010-09-302010-09-30-$0.52
2010-06-302010-06-30-$0.37
2010-03-312010-03-31-$0.33
2009-12-312009-12-31-$0.09
2009-09-302009-09-30-$0.36
2009-06-302009-06-30-$0.27
2009-03-312009-03-31-$0.25
2008-12-312008-12-31-$0.19
2008-09-302008-09-30-$0.42
2008-06-302008-06-30-$0.34
2008-03-312008-03-31-$0.14
2007-12-312007-12-31-$0.19
2007-09-302007-09-30-$0.24
2007-06-302007-06-30-$0.05
2007-03-312007-03-31-$0.04
2006-12-312006-12-31$-0.00
2006-09-302006-09-30$-0.00

Anavex Life Sciences Corp (AVXL) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Anavex Life Sciences Corp (AVXL) Chart:

Anavex Life Sciences Corp (AVXL) News:

Below you will find a list of latest news for Anavex Life Sciences Corp (AVXL) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Anavex Life Sciences Corp (AVXL) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-06-1811.8CALL0 190TRUE00
2026-06-1820.9CALL17 28246.93TRUE-0.25-0.22
2026-06-1830.26CALL42 1106110.06FALSE-0.04-0.13
2026-06-1840.07CALL81 1352115.1FALSE00
2026-06-1850.01CALL11 3578145.25FALSE0.010
2026-06-1860.05CALL0 2737209.8FALSE00
2026-06-1870.04CALL0 1953212.12FALSE00
2026-06-1880.05CALL0 1315268.53FALSE00
2026-06-1890.05CALL0 190258.12FALSE00
2026-06-18100.01CALL0 6816276.65FALSE00
2026-06-18110.03CALL5 387293.08FALSE0.030
2026-06-18120.01CALL0 1680307.82FALSE00
2026-06-18130CALL0 105653.92FALSE00
2026-06-18140CALL0 13669.73FALSE00
2026-06-18150.05CALL0 1914383.34FALSE00
2026-06-18170CALL0 64908.13FALSE00
2026-06-18200CALL0 1712390.18FALSE00
2026-06-18220CALL0 2308542.34FALSE00
2026-06-18250CALL0 140741.66FALSE00
2026-06-18270.1CALL0 268595.72FALSE00
2026-06-1810.15PUT0 19313.4FALSE00
2026-06-1820.05PUT10 917200.68FALSE0.050
2026-06-1830.25PUT35 17294.29TRUE-0.03-0.11
2026-06-1841.25PUT0 3700TRUE00
2026-06-1851.98PUT1 4810TRUE1.980
2026-06-1863.22PUT0 637196.18TRUE00
2026-06-1870PUT0 10TRUE00
2026-06-1884.77PUT0 0368.33TRUE00
2026-06-1890PUT0 00TRUE00
2026-06-18100PUT0 3298TRUE00
2026-06-18110PUT0 0316.04TRUE00
2026-06-18120PUT0 0332.32TRUE00
2026-06-18130PUT0 0347.17TRUE00
2026-06-181411PUT0 60TRUE00
2026-06-18150PUT0 00TRUE00
2026-06-18170PUT0 00TRUE00
2026-06-18200PUT0 00TRUE00
2026-06-18220PUT0 00TRUE00
2026-06-18250PUT0 00TRUE00
2026-06-18270PUT0 00TRUE00
2026-07-1712.2CALL1 1173.43TRUE2.20
2026-07-1720CALL0 1115.98TRUE00
2026-07-1730.44CALL7 229126.02FALSE-0.03-0.06
2026-07-1740.2CALL37 346109.45FALSE0.050.33
2026-07-1750.11CALL26 626132.68FALSE0.010.1
2026-07-1760.15CALL0 1277227.52FALSE00
2026-07-1770.07CALL0 796128.61FALSE00
2026-07-1780.05CALL0 5577143.68FALSE00
2026-07-17100.03CALL0 474167.87FALSE00
2026-07-1710PUT0 00FALSE00
2026-07-1720PUT0 234493.33FALSE00
2026-07-1730.33PUT0 73288.16TRUE00
2026-07-1741.23PUT0 33128.21TRUE00
2026-07-1752.31PUT0 4080.31TRUE00
2026-07-1760PUT0 1138.8TRUE00
2026-07-1770PUT0 3145.52TRUE00
2026-07-1780PUT0 0162.77TRUE00
2026-07-17100PUT0 00TRUE00
2026-10-1610CALL0 00TRUE00
2026-10-1621.37CALL0 1132.31TRUE00
2026-10-1630.55CALL0 10118.19FALSE00
2026-10-1640.43CALL0 29105.79FALSE00
2026-10-1650.25CALL0 171109.34FALSE00
2026-10-1660.15CALL0 8127.14FALSE00
2026-10-1670CALL0 4160.12FALSE00
2026-10-1680CALL0 151144.26FALSE00
2026-10-1690CALL0 2371.45FALSE00
2026-10-1610PUT0 00FALSE00
2026-10-1620.35PUT0 8175.05FALSE00
2026-10-1630.75PUT0 777.44TRUE00
2026-10-1641.45PUT0 2188.34TRUE00
2026-10-1650PUT0 1125.15TRUE00
2026-10-1663.47PUT0 1129.42TRUE00
2026-10-1670PUT0 0107.17TRUE00
2026-10-1685.1PUT1 3118.85TRUE00
2026-10-1690PUT0 0113.87TRUE00
2027-01-1511.97CALL0 4159.4TRUE00
2027-01-1520CALL0 1237.27TRUE00
2027-01-1530.9CALL0 902160.36FALSE00
2027-01-1540.58CALL0 3191.73FALSE00
2027-01-1550.5CALL0 1113114.24FALSE00
2027-01-1560.5CALL0 40190.67FALSE00
2027-01-1570.44CALL0 1373129.06FALSE00
2027-01-15100.22CALL202 6266117.96FALSE0.020.1
2027-01-15120.19CALL0 1715106.13FALSE00
2027-01-15150.15CALL0 1766164.85FALSE00
2027-01-15170.37CALL0 353168.56FALSE00
2027-01-15200.14CALL0 2788142.4FALSE00
2027-01-15220CALL0 350182.18FALSE00
2027-01-15250.35CALL0 487221.79FALSE00
2027-01-15270.35CALL0 173145.41FALSE00
2027-01-1510PUT0 00FALSE00
2027-01-1520.44PUT0 65263.49FALSE00
2027-01-1531.1PUT0 438121.71TRUE00
2027-01-1541.82PUT0 40138.5TRUE00
2027-01-1552.56PUT0 235121.83TRUE00
2027-01-1560PUT0 0110.01TRUE00
2027-01-1574.24PUT0 95177.38TRUE00
2027-01-15107.1PUT0 970TRUE00
2027-01-15120PUT0 18143.2TRUE00
2027-01-15150PUT0 20129.98TRUE00
2027-01-15170PUT0 0175.4TRUE00
2027-01-15200PUT0 2150.14TRUE00
2027-01-15220PUT0 00TRUE00
2027-01-15250PUT0 00TRUE00
2027-01-15270PUT0 00TRUE00
2028-01-2132.85CALL0 5670FALSE00
2028-01-2151.03CALL10 230148.83FALSE1.030
2028-01-2171.15CALL0 87257.47FALSE00
2028-01-21101.01CALL1 37899.61FALSE1.010
2028-01-21120CALL0 157266.9FALSE00
2028-01-21150CALL0 2273.85FALSE00
2028-01-21170.5CALL0 84129.41FALSE00
2028-01-2131.4PUT0 305149.64TRUE00
2028-01-2153.55PUT0 21539.93TRUE00
2028-01-2175.5PUT0 245129.5TRUE00
2028-01-21100PUT0 2792.31TRUE00
2028-01-21120PUT0 20125.47TRUE00
2028-01-21150PUT0 36138.03TRUE00
2028-01-21170PUT0 3125.59TRUE00

Latest AVXL Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST200$7.57
Jun 13, 2022 7:59 PM EST58$7.56
Jun 13, 2022 7:59 PM EST1$7.57
Jun 13, 2022 7:59 PM EST100$7.57
Jun 13, 2022 7:59 PM EST29$7.56

Anavex Life Sciences Corp (AVXL) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000712/0001731122-20-000712-index.htm
2017-06-09UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1314052/000000000017020197/0000000000-17-020197-index.htm
2019-07-11UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1314052/000000000019011025/0000000000-19-011025-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000083423720008231/0000834237-20-008231-index.htm
2020-03-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000083423720009195/0000834237-20-009195-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000090571818000242/0000905718-18-000242-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000090571819000231/0000905718-19-000231-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000090571820000234/0000905718-20-000234-index.htm
2019-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000121390019010249/0001213900-19-010249-index.htm
2019-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000121390019010601/0001213900-19-010601-index.htm
2019-06-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000121390019010604/0001213900-19-010604-index.htm
2019-07-03S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1314052/000121390019012072/0001213900-19-012072-index.htm
2019-07-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1314052/000121390019012578/0001213900-19-012578-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000121390019014791/0001213900-19-014791-index.htm
2019-09-13S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1314052/000121390019018007/0001213900-19-018007-index.htm
2019-09-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000121390019018012/0001213900-19-018012-index.htm
2019-09-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000121390019018023/0001213900-19-018023-index.htm
2019-09-16AWAmendment Withdrawal Requesthttps://www.sec.gov/Archives/edgar/data/1314052/000121390019018132/0001213900-19-018132-index.htm
2019-09-17POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1314052/000121390019018310/0001213900-19-018310-index.htm
2017-06-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1314052/000161577417003075/0001615774-17-003075-index.htm
2017-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577417004118/0001615774-17-004118-index.htm
2017-08-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004281/0001615774-17-004281-index.htm
2017-08-11S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004290/0001615774-17-004290-index.htm
2017-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004399/0001615774-17-004399-index.htm
2017-08-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004574/0001615774-17-004574-index.htm
2017-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004587/0001615774-17-004587-index.htm
2017-08-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004745/0001615774-17-004745-index.htm
2017-08-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004809/0001615774-17-004809-index.htm
2017-08-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004886/0001615774-17-004886-index.htm
2017-09-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004918/0001615774-17-004918-index.htm
2017-09-07424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1314052/000161577417004964/0001615774-17-004964-index.htm
2017-09-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004994/0001615774-17-004994-index.htm
2017-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005014/0001615774-17-005014-index.htm
2017-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005088/0001615774-17-005088-index.htm
2017-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005183/0001615774-17-005183-index.htm
2017-09-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005226/0001615774-17-005226-index.htm
2017-09-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005351/0001615774-17-005351-index.htm
2017-09-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005440/0001615774-17-005440-index.htm
2017-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005508/0001615774-17-005508-index.htm
2017-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005604/0001615774-17-005604-index.htm
2017-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005634/0001615774-17-005634-index.htm
2017-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005731/0001615774-17-005731-index.htm
2017-10-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005767/0001615774-17-005767-index.htm
2017-10-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005807/0001615774-17-005807-index.htm
2017-10-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005861/0001615774-17-005861-index.htm
2017-10-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005929/0001615774-17-005929-index.htm
2017-12-1110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1314052/000161577417007272/0001615774-17-007272-index.htm
2017-12-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417007355/0001615774-17-007355-index.htm
2017-12-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417007357/0001615774-17-007357-index.htm
2018-02-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577418000934/0001615774-18-000934-index.htm
2018-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001587/0001615774-18-001587-index.htm
2018-03-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001629/0001615774-18-001629-index.htm
2018-03-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001650/0001615774-18-001650-index.htm
2018-03-08DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001673/0001615774-18-001673-index.htm
2018-03-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001701/0001615774-18-001701-index.htm
2018-03-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001744/0001615774-18-001744-index.htm
2018-04-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577418002786/0001615774-18-002786-index.htm
2018-04-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418002846/0001615774-18-002846-index.htm
2018-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577418003574/0001615774-18-003574-index.htm
2018-05-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418004019/0001615774-18-004019-index.htm
2018-05-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418004023/0001615774-18-004023-index.htm
2018-07-06424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000161577418006278/0001615774-18-006278-index.htm
2018-07-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577418006280/0001615774-18-006280-index.htm
2018-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577418007805/0001615774-18-007805-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010436/0001615774-18-010436-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010439/0001615774-18-010439-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010441/0001615774-18-010441-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010443/0001615774-18-010443-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010445/0001615774-18-010445-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010447/0001615774-18-010447-index.htm
2018-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010620/0001615774-18-010620-index.htm
2018-12-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1314052/000161577418014328/0001615774-18-014328-index.htm
2019-01-2510-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1314052/000161577419001031/0001615774-19-001031-index.htm
2019-01-31PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1314052/000161577419001498/0001615774-19-001498-index.htm
2019-02-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577419002057/0001615774-19-002057-index.htm
2019-02-11DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314052/000161577419002242/0001615774-19-002242-index.htm
2019-03-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000161577419004136/0001615774-19-004136-index.htm
2019-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577419004139/0001615774-19-004139-index.htm
2019-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577419005452/0001615774-19-005452-index.htm
2019-05-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577419007213/0001615774-19-007213-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/0001615774-19-007324-index.htm
2019-12-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1314052/000173112219000784/0001731122-19-000784-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000018/0001731122-20-000018-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000019/0001731122-20-000019-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000020/0001731122-20-000020-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000021/0001731122-20-000021-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000022/0001731122-20-000022-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000023/0001731122-20-000023-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000024/0001731122-20-000024-index.htm
2020-02-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000103/0001731122-20-000103-index.htm
2020-02-20DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000195/0001731122-20-000195-index.htm
2020-03-23DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000289/0001731122-20-000289-index.htm
2020-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000360/0001731122-20-000360-index.htm
2020-05-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000430/0001731122-20-000430-index.htm
2020-05-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000431/0001731122-20-000431-index.htm
2020-05-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000432/0001731122-20-000432-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000447/0001731122-20-000447-index.htm
2020-07-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000711/0001731122-20-000711-index.htm
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000712/0001731122-20-000712-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000807/0001731122-20-000807-index.htm
2020-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220001047/0001731122-20-001047-index.htm
2020-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220001114/0001731122-20-001114-index.htm
2017-06-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1314052/999999999517001508/9999999995-17-001508-index.htm
2019-07-15EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1314052/999999999519001606/9999999995-19-001606-index.htm
2019-09-20EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1314052/999999999519002138/9999999995-19-002138-index.htm

Anavex Life Sciences Corp (AVXL) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Anavex Life Sciences Corp (AVXL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 363%
Institutional Ownership: 1919%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2017-08-11CHRISTOPHER U MISSLINGPresident and CEOBuy750.003.552,662.501,004,000.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004281/0001615774-17-004281-index.htm
2017-08-14CHRISTOPHER U MISSLINGPresident and CEOBuy375.003.701,387.501,004,375.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004399/0001615774-17-004399-index.htm
2017-08-18CHRISTOPHER U MISSLINGPresident and CEOBuy375.003.811,428.751,004,750.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004574/0001615774-17-004574-index.htm
2017-08-21CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.071,526.251,005,125.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004587/0001615774-17-004587-index.htm
2017-08-24CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.541,702.501,005,500.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004745/0001615774-17-004745-index.htm
2017-08-28CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.441,665.001,005,875.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004809/0001615774-17-004809-index.htm
2017-08-31CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.481,680.001,006,250.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004886/0001615774-17-004886-index.htm
2017-09-05CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.901,837.501,006,625.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004918/0001615774-17-004918-index.htm
2017-09-07CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.761,785.001,007,000.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004994/0001615774-17-004994-index.htm
2017-09-11CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.811,803.751,007,375.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005014/0001615774-17-005014-index.htm
2017-09-14CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.581,717.501,007,750.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005088/0001615774-17-005088-index.htm
2017-09-18CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.401,650.001,008,125.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005183/0001615774-17-005183-index.htm
2017-09-20CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.231,586.251,008,500.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005226/0001615774-17-005226-index.htm
2017-09-26CHRISTOPHER U MISSLINGPresident and CEOBuy375.003.881,455.001,008,875.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005351/0001615774-17-005351-index.htm
2017-09-28CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.211,578.751,009,250.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005440/0001615774-17-005440-index.htm
2017-10-02CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.201,575.001,009,625.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005508/0001615774-17-005508-index.htm
2017-10-05CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.301,612.501,010,000.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005604/0001615774-17-005604-index.htm
2017-10-13CHRISTOPHER U MISSLINGPresident and CEOBuy750.004.223,165.001,010,750.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005731/0001615774-17-005731-index.htm
2017-10-17CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.271,601.251,011,125.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005767/0001615774-17-005767-index.htm
2017-10-19CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.491,683.751,011,500.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005807/0001615774-17-005807-index.htm
2017-10-24CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.921,845.001,011,875.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005861/0001615774-17-005861-index.htm
2017-10-25CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.391,646.251,012,250.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005929/0001615774-17-005929-index.htm
2018-03-02CHRISTOPHER U MISSLINGDirector, President & CEOBuy1,650.002.413,976.501,013,900.00https://www.sec.gov/Archives/edgar/data/1314052/000161577418001587/0001615774-18-001587-index.htm
2018-03-05CHRISTOPHER U MISSLINGPresident and CEOBuy1,500.002.633,945.001,015,400.00https://www.sec.gov/Archives/edgar/data/1314052/000161577418001629/0001615774-18-001629-index.htm
2018-03-06CHRISTOPHER U MISSLINGPresident and CEOBuy1,450.002.733,958.501,016,850.00https://www.sec.gov/Archives/edgar/data/1314052/000161577418001650/0001615774-18-001650-index.htm
2018-03-07CHRISTOPHER U MISSLINGPresident and CEOBuy1,360.002.923,971.201,018,210.00https://www.sec.gov/Archives/edgar/data/1314052/000161577418001744/0001615774-18-001744-index.htm